Corundum Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.56M | Buy |
25,726
+2,092
| +9% | +$122K | 0.52% | 40 |
|
|
2025
Q4 | $1.27M | Sell |
23,634
-1,811
| -7% | -$87.1K | 0.43% | 46 |
|
|
2025
Q3 | $1.15M | Sell |
25,445
-33
| -0.1% | -$1.54K | 0.47% | 50 |
|
|
2025
Q2 | $1.18M | Buy |
25,478
+140
| +0.6% | +$6.87K | 0.52% | 47 |
|
|
2025
Q1 | $1.55M | Sell |
25,338
-18,196
| -42% | -$1.06M | 0.74% | 27 |
|
|
2024
Q4 | $2.46M | Buy |
43,534
+17,596
| +68% | +$983K | 0.92% | 28 |
|
|
2024
Q3 | $1.34M | Sell |
25,938
-2,257
| -8% | -$106K | 0.61% | 31 |
|
|
2024
Q2 | $1.17M | Buy |
28,195
+17,693
| +168% | +$792K | 0.46% | 62 |
|
|
2024
Q1 | $570K | Buy |
10,502
+6,084
| +138% | +$310K | 0.27% | 66 |
|
|
2023
Q4 | $227K | Sell |
4,418
-3,470
| -44% | -$182K | 0.11% | 94 |
|
|
2023
Q3 | $458K | Sell |
7,888
-953
| -11% | -$58.4K | 0.26% | 69 |
|
|
2023
Q2 | $565K | Sell |
8,841
-6,526
| -42% | -$438K | 0.28% | 71 |
|
|
2023
Q1 | $1.07M | Buy |
15,367
+7,617
| +98% | +$537K | 0.5% | 60 |
|
|
2022
Q4 | $558K | Buy |
7,750
+387
| +5% | +$29.2K | 0.32% | 71 |
|
|
2022
Q3 | $523K | Buy |
7,363
+423
| +6% | +$30.7K | 0.33% | 68 |
|
|
2022
Q2 | $534K | Sell |
6,940
-1,413
| -17% | -$108K | 0.36% | 67 |
|
|
2022
Q1 | $610K | Buy |
8,353
+249
| +3% | +$16.7K | 0.57% | 69 |
|
|
2021
Q4 | $505K | Buy |
8,104
+866
| +12% | +$50.8K | 0.33% | 57 |
|
|
2021
Q3 | $428K | Buy |
7,238
+861
| +14% | +$56.7K | 0.32% | 52 |
|
|
2021
Q2 | $426K | Buy |
6,377
+981
| +18% | +$64K | 0.28% | 52 |
|
|
2021
Q1 | $341K | Buy |
5,396
+319
| +6% | +$19.8K | 0.27% | 60 |
|
|
2020
Q4 | $315K | Buy |
5,077
+190
| +4% | +$11.7K | 0.26% | 57 |
|
|
2020
Q3 | $295K | Buy |
4,887
+459
| +10% | +$27.6K | 0.29% | 51 |
|
|
2020
Q2 | $260K | Sell |
4,428
-373
| -8% | -$22.3K | 0.31% | 40 |
|
|
2020
Q1 | $268K | Sell |
4,801
-540
| -10% | -$33K | 0.38% | 38 |
|
|
2019
Q4 | $343K | Buy |
5,341
+184
| +4% | +$10.5K | 0.36% | 37 |
|
|
2019
Q3 | $262K | Sell |
5,157
-3
| -0.1% | -$141 | 0.3% | 46 |
|
|
2019
Q2 | $234K | Buy |
5,160
+38
| +0.7% | +$1.77K | 0.27% | 51 |
|
|
2019
Q1 | $244K | Buy |
+5,122
| New | +$255K | 0.28% | 44 |
|
|
2018
Q2 | $225K | Buy |
4,069
+189
| +5% | +$10.2K | 0.28% | 44 |
|
|
2018
Q1 | $245K | Sell |
3,880
-798
| -17% | -$51.3K | 0.26% | 38 |
|
|
2017
Q4 | $287K | Buy |
4,678
+4
| +0.1% | +$250 | 0.31% | 35 |
|
|
2017
Q3 | $298 | Buy |
+4,674
| New | +$273K | 0.31% | 31 |
|
Other funds holding BMY
VCM
VPM
Corundum Group's BMY Position: Q1 2026 in Review
Corundum Group increased its Bristol-Myers Squibb (BMY) stake by 8.9% in Q1 2026, buying an estimated $122K and bringing the position to 25,726 shares worth $1.56M. The position accounts for 0.52% of the portfolio, ranked #40.
Corundum Group first reported a position in BMY in Q3 2017 and has held it in 33 quarters since. The position peaked at $2.46M in Q4 2024. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Corundum Group held 25,726 shares of Bristol-Myers Squibb worth $1.56M as of Q1 2026.
- Corundum Group bought 2,092 Bristol-Myers Squibb shares in Q1 2026, an estimated $122K.
- Bristol-Myers Squibb made up 0.52% of Corundum Group's portfolio in Q1 2026, its #40 holding.
- Corundum Group first reported a position in Bristol-Myers Squibb in Q3 2017 and has held it in 33 quarters since.
- Corundum Group's Bristol-Myers Squibb position peaked at $2.46M in Q4 2024.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Corundum Group's 13F filing for Q1 2026, filed 20 Apr 2026.